Advanced Heart Care, LLC

Summary

Advanced Heart Care, LLC is a medical facility located in Bridgewater, New Jersey. This center is recognized for care of Heart Failure, Cardiovascular Disease, Heart Attack, Stroke, Coronary Artery Disease and other specialties. Advanced Heart Care, LLC is involved with conducting 19 clinical trials across 35 conditions. There are 1 research doctors associated with this hospital, such as Sharan Mahal, MD.

Top PIs

Clinical Trials running at Advanced Heart Care, LLC

Heart Failure

Cardiovascular Disease

Type 2 Diabetes

Obesity

Coronary Artery Disease

Percutaneous Coronary Intervention

Hypercholesterolemia

Angioplasty

Hypertension

High Blood Pressure

Omecamtiv Mecarbil

for Heart Failure

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Recruiting

1 award

Phase 3

10 criteria

Vicadrostat + Empagliflozin

for Heart Failure

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between 1 and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, must go to hospital due to heart failure, or die during the study. The time until these events are observed is compared between the treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

1 criteria

Maridebart Cafraglutide

for Heart Failure

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Recruiting

1 award

Phase 3

3 criteria